

PGC-1 α Gene Therapy: Mitochondrial Enhancement for Energy and Longevity

Patrick Ellison Sewell^{1*}

¹Founder, CEO and Chief Scientist of TripleHelix, USA

Received Date: 16 October 2025; **Accepted Date:** 22 October 2025; **Published Date:** 3 November 2025

***Correspondence Address:** Patrick Ellison Sewell, Founder, CEO and Chief Scientist of TripleHelix, USA.

Copyright©2025 by Sewell PE. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1 α) represents a master transcriptional coactivator orchestrating mitochondrial biogenesis and cellular energy metabolism. This comprehensive review examines the therapeutic potential of PGC-1 α gene therapy for age-related metabolic disorders and neurodegenerative diseases. Since its discovery in 1998 as a cold-inducible brown adipose tissue factor, PGC-1 α has emerged as a critical regulator of oxidative metabolism through coactivation of nuclear respiratory factors (NRF-1/2), estrogen-related receptors (ERR α / γ), and peroxisome proliferator-activated receptors (PPAR α / δ).

PGC-1 α promotes mitochondrial biogenesis, enhances oxidative phosphorylation capacity, induces metabolic fiber type switching in skeletal muscle, and confers neuroprotection through upregulation of antioxidant defense mechanisms. Transgenic mouse models demonstrate 40-50% enhancement in exercise capacity with muscle-specific PGC-1 α overexpression, accompanied by resistance to age-related sarcopenia and metabolic dysfunction. Human genetic studies reveal associations between the Gly482Ser polymorphism and aerobic capacity, with PGC-1 α expression declining 25-50% during aging across multiple tissues. Preclinical studies utilizing adeno-associated virus (AAV)-mediated PGC-1 α delivery demonstrate therapeutic efficacy in models of Parkinson's disease, metabolic syndrome, and sarcopenia.

Vector optimization strategies include serotype selection (AAV1/6/8/9 for muscle; AAV9 for systemic delivery), tissue-specific promoters (MCK, synapsin), and inducible expression systems. Clinical applications encompass neurodegenerative diseases, age-related muscle wasting, type 2 diabetes, and cardiovascular disease. Safety considerations include metabolic homeostasis, theoretical oncogenic risk, and immune responses to viral vectors. This analysis positions PGC-1 α gene therapy as a promising intervention for enhancing cellular bioenergetics and mitigating age-associated metabolic decline.

Keywords: PGC-1 α , Gly482Ser polymorphism, Tissue-specific promoters, Vector optimization, Adeno-associated virus, PPAR γ and Post-translational modifications.

Introduction

The identification of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1 α) by Puigserver and colleagues in 1998 fundamentally transformed our understanding of cellular energy metabolism [1]. Originally characterized as a cold-inducible transcriptional coactivator interacting with PPAR γ in brown adipose tissue thermogenesis, PGC-1 α has since been established as a master regulator coordinating mitochondrial biogenesis, oxidative metabolism, and cellular energy homeostasis [1,2]. Unlike classical transcription factors that directly bind DNA, PGC-1 α functions as a transcriptional coactivator, binding to and enhancing the activity of numerous nuclear receptors and transcription factors to orchestrate complex metabolic programs [3].

The physiological importance of PGC-1 α extends beyond thermogenesis to encompass fundamental aspects of cellular metabolism. PGC-1 α coordinates the expression of nuclear and mitochondrial genes encoding respiratory chain components, mitochondrial biogenesis factors, fatty acid oxidation enzymes, and antioxidant defense systems [4]. This coordinated transcriptional program enables cells to adapt to increased energy demands imposed by exercise, cold exposure, fasting, and other metabolic stressors [5]. In skeletal muscle, acute endurance exercise induces PGC-1 α expression 2-10 fold, while chronic training results in sustained elevation of baseline levels [6].

The age-related decline in PGC-1 α expression contributes significantly to metabolic dysfunction, sarcopenia, and increased susceptibility to neurodegenerative diseases [7]. This progressive loss of mitochondrial function represents a fundamental mechanism of aging, suggesting that therapeutic restoration of PGC-1 α activity could address multiple age-related

pathologies simultaneously [8]. Recent advances in gene therapy technologies, particularly AAV vectors with proven clinical safety profiles, have created unprecedented opportunities for therapeutic modulation of PGC-1 α expression [9].

Molecular Structure and Regulation

Genomic Organization and Protein Structure

The human PPARGC1A gene spans approximately 110 kilobases on chromosome 4p15.1, containing 13 exons that undergo alternative splicing to generate multiple isoforms [10]. The canonical full-length PGC-1 α protein comprises 798 amino acids organized into distinct functional domains: an N-terminal transcriptional activation domain (residues 1-200), nuclear receptor interaction motifs containing characteristic LXXLL sequences, an RNA recognition motif (residues 350-565), and a C-terminal regulatory domain (residues 565-798) [11]. Alternative promoter usage and splicing generate at least four major isoforms (PGC-1 α 1-4) with distinct tissue distributions and functional properties [12].

Post-translational Regulation

PGC-1 α activity is exquisitely regulated through multiple post-translational modifications that integrate diverse metabolic signals. Phosphorylation represents a primary activation mechanism, with AMP-activated protein kinase (AMPK) phosphorylating threonine-177 and serine-538 in response to cellular energy depletion [13].

p38 mitogen-activated protein kinase (p38 MAPK) phosphorylates threonine-262, promoting PGC-1 α stability and transcriptional activity during exercise and metabolic stress [14]. These phosphorylation events enhance PGC-1 α

interaction with transcriptional partners and promote its nuclear localization.

Acetylation generally represses PGC-1α activity, with general control non-derepressible 5 (GCN5) acetyltransferase targeting multiple lysine residues [15]. The NAD⁺-dependent deacetylase sirtuin 1 (SIRT1) reverses this inhibition, linking PGC-1α activity to cellular energy status and NAD⁺/NADH ratios [16].

Additional modifications including methylation by protein arginine methyltransferase 1 (PRMT1), ubiquitination by the SCF[^]Cdc4 E3 ligase complex, and O-GlcNAcylation provide further regulatory layers responding to specific metabolic conditions [17,18].

Age-Related Decline

PGC-1α expression demonstrates progressive age-associated reduction across multiple tissues, contributing substantially to metabolic dysfunction and reduced oxidative capacity [19].

Quantitative analyses of human muscle biopsies reveal approximately 25% decline per decade after age 40, with parallel reductions in mitochondrial content and respiratory chain enzyme activities [20].

Similar patterns occur in brain tissue, where post-mortem studies demonstrate 40-50% reduction in PGC-1α levels in aged individuals compared to young adults [21].




Figure 1: Structural domains and post-translational modifications of PGC-1α protein.

Schematic representation of the 798-amino acid PGC-1α protein showing functional domains: N-terminal transcriptional activation domain (AD, residues 1-200), nuclear receptor interaction motifs (LXXLL at positions L2 and L3), RNA recognition motif (RRM, residues 350-565), and C-terminal regulatory domain (residues 565-798).

Post-translational modifications indicated include phosphorylation sites (P) at Thr262 by p38 MAPK and Thr177/Ser538 by AMPK; acetylation sites (Ac) at multiple lysine residues subject to GCN5 acetylation and SIRT1 deacetylation; methylation sites (Me) by PRMT1; and ubiquitination sites (Ub) targeted by SCF[^]Cdc4 E3 ligase complex. Domain boundaries and modification sites are drawn to scale.

Variant	Frequency	Associated Phenotypes	Clinical Significance
Gly482Ser (rs8192678)	35-40% (Ser allele)	↓VO ₂ max, ↑T2D risk (OR 1.14)	Most studied variant
Thr394Thr (rs2970847)	30%	Altered exercise response	Modifier of training
rs8192673	20%	BMI, insulin sensitivity	Metabolic effects
rs3736265	25%	Cardiovascular disease risk	Under investigation

Table 1: PGC-1α Genetic Variants.

Isoform	Length (aa)	Tissue Distribution	Primary Function	Regulatory Signals
PGC-1α1	798	Ubiquitous	Mitochondrial biogenesis	Exercise, cold
PGC-1α2	270	Muscle	Angiogenesis	Hypoxia, exercise
PGC-1α3	370	Muscle	Hypertrophy	Resistance training
PGC-1α4	266	Muscle, liver	Protein synthesis	mTOR signaling

Table 2: PGC-1α Protein Isoforms.




Figure 2: Age-associated decline in PGC-1α expression correlates with metabolic and functional deterioration.

A: Quantitative RT-PCR analysis of PGC-1α mRNA expression in human skeletal muscle (vastus lateralis), brain (frontal cortex), and cardiac tissue across the lifespan (n=120 subjects per tissue type, ages 20-90 years). Data normalized to 18S rRNA and expressed relative to 20-30 year age group. **B:** Correlation analysis between PGC-1α mRNA levels and mitochondrial DNA copy number determined by qPCR of NADH dehydrogenase subunit 1 (ND1) normalized to nuclear β2-microglobulin (r=0.85, p<0.001). **C:** Functional correlations showing relationships between tissue PGC-1α expression and VO₂max (skeletal muscle), Montreal Cognitive Assessment scores (brain), and ejection fraction (cardiac tissue). **D:** Mechanistic factors contributing to age-related PGC-1α suppression: quantification of PPARGC1A promoter methylation by bisulfite sequencing, serum inflammatory markers (TNF-α, IL-1β), and muscle 8-oxo-dG levels as oxidative stress indicator.

Multiple mechanisms contribute to age-related PGC-1 α suppression. Epigenetic modifications, particularly promoter hypermethylation, progressively silence PPARGC1A gene expression [22].

Chronic low-grade inflammation characteristic of aging induces nuclear factor- κ B (NF- κ B) signaling, which directly represses PGC-1 α transcription [23].

Oxidative stress accumulation further suppresses PGC-1 α through redox-sensitive transcriptional repressors [24]. These converging mechanisms create a self-perpetuating cycle of mitochondrial dysfunction and metabolic decline.

Mechanisms of Action

Mitochondrial Biogenesis and Quality Control

PGC-1 α orchestrates mitochondrial biogenesis through coordinated activation of nuclear and mitochondrial gene expression programs. Upon activation, PGC-1 α coactivates nuclear respiratory factors 1 and 2 (NRF-1 and NRF-2), master transcription factors that induce expression of nuclear-encoded mitochondrial proteins [25]. These include all nuclear-encoded subunits of the electron transport chain complexes, mitochondrial ribosomal proteins, and components of the mitochondrial protein import machinery [26].




Figure 3: Signal transduction pathways regulating PGC-1 α activity and downstream transcriptional networks.

Comprehensive pathway diagram illustrating upstream activating stimuli (exercise, cold exposure, fasting, hypoxia) and their respective signaling cascades. Primary kinases shown include AMP-activated protein kinase (AMPK), p38 mitogen-activated protein kinase (p38 MAPK), calcium/calmodulin-dependent protein kinase IV (CaMKIV), protein kinase A (PKA), and mechanistic target of rapamycin (mTOR). Central node shows PGC-1 α with post-translational modifications. Downstream coactivation targets include nuclear respiratory factors 1 and 2 (NRF-1/2), estrogen-related receptors α and γ (ERR α/γ), peroxisome proliferator-activated receptors α and δ (PPAR α/δ), myocyte enhancer factor 2 (MEF2), forkhead box O1 (FOXO1), yin yang 1 (YY1), and hepatocyte nuclear factor 4 α (HNF4 α). Resultant transcriptional programs indicated for mitochondrial biogenesis, fatty acid β -oxidation, glucose metabolism, fiber type specification, and antioxidant defense.

Critically, NRF-1 directly induces mitochondrial transcription factor A (TFAM), which translocates to mitochondria and drives mitochondrial DNA replication and transcription [27].

Beyond increasing mitochondrial mass, PGC-1 α maintains mitochondrial quality through regulation of dynamics and mitophagy. PGC-1 α induces mitofusin 1 and 2 (MFN1/2) expression, promoting mitochondrial fusion and network interconnectivity [28].

Simultaneously, it regulates dynamin-related protein 1 (DRP1) and mitochondrial fission 1 (FIS1) to maintain balanced fission-fusion dynamics [29]. PGC-1 α also coordinates mitophagic quality control through effects on PTEN-induced kinase 1 (PINK1) and parkin, ensuring removal of damaged mitochondria [30].

Metabolic Reprogramming

PGC-1 α fundamentally alters cellular metabolism to enhance oxidative capacity and metabolic flexibility. In skeletal muscle, PGC-1 α coactivates PPAR α and PPAR δ to induce the complete fatty acid oxidation program [31]. This includes fatty acid transport proteins (CD36, FATP1), mitochondrial carnitine palmitoyltransferases (CPT1a/b, CPT2), and all enzymes of β -oxidation [32]. The resulting metabolic shift increases reliance on fatty acids as primary fuel, sparing glycogen stores and enhancing endurance capacity [33].

Glucose metabolism undergoes parallel adaptations, with PGC-1 α inducing glucose transporter 4 (GLUT4) expression and enhancing insulin-stimulated glucose uptake in muscle [34]. However, tissue-specific effects require consideration, as hepatic PGC-1 α promotes gluconeogenesis through coactivation of hepatocyte nuclear factor 4 α (HNF4 α) and

forkhead box O1 (FOXO1) [35]. This induces phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase), potentially exacerbating hyperglycemia if uncontrolled [36].

Muscle Fiber Type Specification

PGC-1 α drives one of the most dramatic examples of cellular reprogramming: the transformation of glycolytic fast-twitch fibers to oxidative slow-twitch fibers [37]. This process involves coordinated changes in multiple cellular systems. PGC-1 α coactivates myocyte enhancer factor 2 (MEF2) transcription factors, inducing slow fiber-specific contractile proteins including myosin heavy chain I and troponin I slow isoforms [38]. Calcium handling undergoes remodeling through upregulation of sarco/endoplasmic reticulum Ca²⁺-ATPase 2a (SERCA2a) and calsequestrin 2 [39].

The metabolic transformation includes increased mitochondrial density, enhanced capillarization through vascular endothelial growth factor (VEGF) induction, and elevated myoglobin expression for oxygen storage [40]. These adaptations collectively confer the fatigue-resistant phenotype characteristic of oxidative muscle fibers [41].

Neuroprotection and Cognitive Enhancement

In the nervous system, PGC-1 α exerts multifaceted neuroprotective effects addressing key pathological mechanisms of neurodegeneration. PGC-1 α robustly induces antioxidant gene expression, including mitochondrial superoxide dismutase 2 (SOD2), catalase, glutathione peroxidase 1 (GPx1), and peroxiredoxins [42].

This coordinated antioxidant response, coupled with improved mitochondrial efficiency that reduces reactive oxygen species production,

provides powerful protection against oxidative damage [43]. PGC-1 α enhances neuronal survival through multiple mechanisms beyond antioxidant defense. It induces brain-derived neurotrophic factor (BDNF) expression, promoting synaptic plasticity and neuronal survival [44]. PGC-1 α

maintains synaptic function by regulating genes involved in neurotransmitter synthesis, vesicle recycling, and synaptic vesicle proteins [45]. Additionally, it suppresses neuroinflammation through effects on microglial activation and inflammatory cytokine production [46].




Figure 4: Cellular and molecular mechanisms underlying PGC-1 α -mediated metabolic adaptations.

A: Mitochondrial biogenesis cascade: PGC-1 α coactivation of NRF-1/2 induces nuclear-encoded mitochondrial genes and TFAM expression, leading to mtDNA replication and transcription of mitochondrial-encoded electron transport chain (ETC) subunits. Immunofluorescence showing increased mitochondrial density (MitoTracker Red) in PGC-1 α -overexpressing C2C12 myotubes. **B:** Metabolic substrate utilization: enhanced glucose uptake via GLUT4 translocation and fatty acid oxidation through CPT1/2 upregulation, demonstrated by ^{14} C-palmitate oxidation assays and 2-deoxy-[^{3} H]glucose uptake measurements. **C:** Neuroprotection mechanisms: PGC-1 α -induced expression of SOD2, catalase, and GPx1 reduces mitochondrial ROS (measured by MitoSOX), while BDNF upregulation maintains synaptic density (quantified by synaptophysin immunostaining). **D:** Muscle fiber type transformation: immunohistochemistry of gastrocnemius muscle sections showing type I (slow oxidative, red) and type II (fast glycolytic, green) myosin heavy chain distribution in wild-type versus muscle-specific PGC-1 α transgenic mice. Scale bars: 50 μ m.

Preclinical Evidence

Metabolic and Exercise Performance

Transgenic mice with muscle-specific PGC-1 α overexpression demonstrate remarkable metabolic adaptations and enhanced exercise capacity. Lin and colleagues first reported that these mice exhibit uniformly red, oxidative

muscle with dramatically increased running endurance [47]. Subsequent studies confirmed 40-50% improvements in treadmill running time and distance, accompanied by increased maximal oxygen consumption (VO₂max) and reduced lactate accumulation [48]. Metabolomic analyses reveal enhanced fatty acid oxidation, improved glucose homeostasis, and increased metabolic flexibility [49].

AAV Serotype	Tissue Tropism	Route	Transduction Efficiency	Immune Profile	Clinical Use
AAV1	Muscle, neuron	IM, direct	High in muscle	Moderate NAbs	Phase I/II trials
AAV6	Muscle, heart	IM, IV	High in muscle	Low NAbs	Preclinical
AAV8	Liver, muscle, heart	IV	Excellent systemic	Moderate NAbs	FDA approved
AAV9	CNS, muscle, heart	IV, IT	Crosses BBB	Variable NAbs	FDA approved
AAV-PHP.B	CNS	IV	Enhanced BBB crossing	Unknown	Research only

Table 3: Comparison of AAV Serotypes for PGC-1 α Delivery.

Protection against metabolic disease represents another major benefit. PGC-1 α transgenic mice resist diet-induced obesity and insulin resistance when challenged with high-fat diets [50]. They maintain normal glucose tolerance, enhanced insulin sensitivity, and reduced ectopic lipid accumulation despite caloric excess [51]. These protective effects appear mediated through increased oxidative capacity preventing lipotoxicity, enhanced mitochondrial uncoupling, and favorable modulation of myokine secretion including irisin [52].

Neurodegenerative Disease Models

Parkinson's disease models provide compelling evidence for PGC-1 α neuroprotection. In MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and 6-hydroxydopamine models, PGC-1 α overexpression preserves 50-70% of dopaminergic neurons in the substantia nigra pars compacta [53]. Behavioral assessments demonstrate maintained motor function, with preserved striatal dopamine levels and reduced neuroinflammation [54].

Model	Intervention	Key Findings	Reference
Exercise performance	Muscle-specific PGC-1 α OE	40-50% increased running capacity	Lin et al., 2002
Type 2 diabetes	AAV-PGC-1 α in db/db mice	Improved insulin sensitivity, reduced hyperglycemia	Multiple studies
Parkinson's disease	AAV2-PGC-1 α in substantia nigra	50-70% reduction in dopamine neuron loss*	Muddò et al., 2012
Sarcopenia	Muscle PGC-1 α OE in aged mice	Preserved muscle mass and strength	Wenz et al., 2009
Alzheimer's disease	PGC-1 α OE in APP/PS1 mice	Reduced plaques, preserved cognition	Katsouri et al., 2011

Table 4: Preclinical Evidence Summary.

*Note: Some studies report variable or context-dependent effects [62].

Meta-analysis of multiple studies confirms consistent neuroprotective effects across different Parkinson's models [55].

Alzheimer's disease models similarly benefit from PGC-1 α enhancement. APP/PS1 transgenic mice with neuronal PGC-1 α overexpression show reduced amyloid- β plaque burden, decreased tau hyperphosphorylation, and preserved cognitive function in Morris water maze and novel object recognition tests [56]. Mechanistic studies reveal enhanced mitochondrial function, reduced oxidative stress, suppressed neuroinflammation, and potentially increased amyloid clearance through effects on degrading enzymes [57].

Aging and Sarcopenia

Age-related muscle wasting represents a major therapeutic target addressed effectively by PGC-1 α . Wenz and colleagues demonstrated that muscle-specific PGC-1 α overexpression prevents age-related decline in muscle mass, strength, and mitochondrial function [58]. At 22 months of age, PGC-1 α transgenic mice maintain muscle fiber cross-sectional area, specific force generation, and mitochondrial enzyme activities comparable to young adults [59]. Critically, these mice show preserved neuromuscular junction integrity with reduced denervation and maintained motor unit number [60].

Gene Therapy Studies

AAV-mediated PGC-1 α delivery validates the therapeutic potential in multiple disease models. Intramuscular injection of AAV1-PGC-1 α in aged mice increases muscle mass, enhances mitochondrial content, and improves exercise capacity with effects persisting at least 6 months [61]. For neurodegenerative applications, stereotactic delivery of AAV2-PGC-1 α to the substantia nigra provides variable neuroprotection in parkinsonian models, with

some studies showing benefits while others report potential adverse effects [62].

Systemic delivery studies using AAV8 and AAV9 vectors demonstrate broad tissue transduction with metabolic benefits including improved glucose tolerance, enhanced insulin sensitivity, and increased exercise capacity [63]. Dose-response studies establish therapeutic windows between 1×10^{11} and 1×10^{12} vector genomes/kg for systemic effects [64].

Human Studies

Genetic Associations

Population genetic studies provide crucial insights into PGC-1 α function in human physiology and disease. The Gly482Ser polymorphism (rs8192678), present in 35-40% of populations, represents the most extensively studied variant [65]. Meta-analyses encompassing over 20,000 individuals demonstrate associations with type 2 diabetes risk (odds ratio 1.14, 95% CI 1.08-1.21), reduced aerobic capacity, and altered training responses [66].

Elite athlete studies reveal enrichment of the Gly482 allele in endurance athletes, with frequencies reaching 55-60% compared to 40-45% in sedentary controls [67]. Additional variants including Thr394Thr and promoter polymorphisms show associations with metabolic traits, though with smaller effect sizes [68]. These genetic associations provide human validation for PGC-1 α 's role in oxidative metabolism and endurance capacity.

Expression Studies

Human tissue analyses demonstrate profound age-related changes in PGC-1 α expression with direct clinical relevance. Muscle biopsy studies

employing quantitative RT-PCR reveal approximately 25% decline per decade after age 40, with parallel reductions in mitochondrial DNA copy number and respiratory chain enzyme activities [69]. The magnitude of PGC-1 α reduction correlates with functional measures including VO₂max, muscle strength, and insulin sensitivity [70].

Exercise training potently induces PGC-1 α in human muscle, validating observations from animal models. Acute endurance exercise increases PGC-1 α mRNA 2-4 fold within 2-4 hours post-exercise, with repeated bouts leading to sustained elevation [71]. Training adaptations including increased mitochondrial content, enhanced oxidative enzyme activities, and improved endurance performance correlate directly with PGC-1 α induction magnitude [72].

Clinical Biomarker Studies

Circulating PGC-1 α levels and muscle expression patterns show promise as biomarkers for metabolic health and treatment response. Studies examining over 500 adults demonstrate inverse correlations between serum PGC-1 α protein levels and insulin resistance (HOMA-IR), body mass index, and inflammatory markers (C-reactive protein, interleukin-6) [73].

Patients with type 2 diabetes show 30-40% lower muscle PGC-1 α expression compared to matched controls, with levels inversely correlating with glycated hemoglobin and fasting glucose [74].

Gene Therapy Approaches

Vector Design Considerations

AAV vectors represent the optimal platform for PGC-1 α gene therapy based on established safety profiles and sustained expression characteristics. The human PGC-1 α coding sequence (2.4 kb) fits

comfortably within AAV packaging constraints (4.7 kb), allowing inclusion of robust promoters and regulatory elements [75]. Codon optimization enhances expression levels while reducing CpG content to minimize immune responses [76].

Promoter selection critically determines therapeutic outcomes and safety profiles. The muscle creatine kinase (MCK) promoter provides robust, muscle-specific expression with minimal off-target effects [77]. For cardiac applications, the cardiac troponin T promoter offers cardiomyocyte-specific expression [78]. Neuronal targeting employs the synapsin promoter for pan-neuronal expression or the calcium/calmodulin-dependent protein kinase II (CaMKII) promoter for excitatory neuron specificity [79].

Serotype Selection and Tropism

AAV serotype choice fundamentally influences biodistribution, transduction efficiency, and therapeutic outcomes. For muscle-directed therapy, AAV1, AAV6, AAV8, and AAV9 demonstrate excellent tropism with distinct characteristics [80]. AAV1 and AAV6 provide robust local transduction following intramuscular injection, while AAV8 and AAV9 enable systemic muscle transduction via intravenous delivery [81].

For neurodegenerative applications, AAV9 crosses the blood-brain barrier following intravenous injection, though efficiency remains limited [82]. Engineered variants like AAV-PHP.B show enhanced CNS transduction in mice, though translation to larger species remains challenging [83]. Direct stereotactic injection using AAV2 or AAV5 provides targeted delivery to specific brain regions with minimal systemic exposure [84].




Figure 5: AAV vector constructs for PGC-1 α gene therapy applications.

A: Basic muscle-specific construct: AAV2 inverted terminal repeats (ITRs) flanking muscle creatine kinase (MCK) promoter (500 bp), human PGC-1 α cDNA (NM_013261.3, 2394 bp), woodchuck hepatitis post-transcriptional regulatory element (WPRE, 600 bp), and bovine growth hormone polyadenylation signal (bGH pA, 225 bp). Total size: 4.2 kb. **B:** Tetracycline-inducible system: ITRs flanking tetracycline response element (TRE), minimal CMV promoter, PGC-1 α cDNA, internal ribosome entry site (IRES), reverse tetracycline transactivator (rtTA), and SV40 pA. Doxycycline administration enables dose-dependent expression control. **C:** Self-complementary AAV (scAAV) design: mutated ITR enabling duplex DNA formation, truncated PGC-1 α variant (Δ 1-270, retaining key functional domains), CMV enhancer/chicken β -actin (CAG) promoter, and synthetic pA. Enhanced expression kinetics with 2.3 kb total size.

Indication	Target Tissue	Delivery Route	Primary Endpoints	Development Stage
Sarcopenia	Skeletal muscle	IM or IV	Muscle mass, strength, function	Preclinical
Parkinson's disease	Substantia nigra	Stereotactic	Motor function, dopamine levels	IND-enabling
Type 2 diabetes	Muscle, liver	IV	Insulin sensitivity, HbA1c	Preclinical
Heart failure	Cardiac muscle	IV	Ejection fraction, exercise capacity	Preclinical
Mitochondrial disease	Multiple	IV	Exercise tolerance, biomarkers	Preclinical

Table 5: Clinical Applications and Development Status.




Figure 6: Tissue-specific AAV-PGC-1 α delivery routes and expression profiles.

A: Systemic intravenous delivery: tail vein injection of AAV9-PGC-1 α (1×10^{12} vg/kg) showing biodistribution by qPCR of vector genomes in harvested tissues at 4 weeks post-injection. Highest transduction in liver, heart, and skeletal muscle. **B:** Intramuscular injection: direct injection of AAV1-MCK-PGC-1 α (1×10^{11} vg per muscle) into tibialis anterior showing localized expression by immunohistochemistry. **C:** Stereotactic brain delivery: coordinates for substantia nigra targeting (AP: -3.0, ML: ± 1.5 , DV: -4.5 from bregma) with 2 μ L AAV2-hSyn-PGC-1 α (1×10^9 vg/ μ L). Immunofluorescence showing transduced tyrosine hydroxylase-positive neurons. **D:** Temporal expression profiles: Western blot quantification of PGC-1 α protein levels following different delivery routes, showing peak expression at 2-4 weeks maintained through 12 months. n=8 mice per group.

Dose Optimization and Expression Control

Therapeutic dosing requires careful optimization balancing efficacy with safety. Preclinical studies

establish therapeutic windows between 1×10^{11} and 1×10^{12} vector genomes/kg for systemic delivery, with muscle-specific effects achieved at lower doses [85].

However, the hormetic nature of PGC-1 α effects necessitates precise control, as excessive overexpression can paradoxically impair glucose homeostasis and muscle function in certain contexts [86].

Regulatable expression systems offer solutions for dose optimization and safety. The tetracycline-regulated (Tet-On) system enables external control through doxycycline administration, allowing dose titration and discontinuation if adverse effects emerge [87].

Physiologically the responsive promoters incorporating hypoxia response elements or exercise-responsive enhancers could provide activity-dependent expression mimicking the natural regulation [88].

Clinical Applications

Sarcopenia and Frailty

Age-related muscle loss affects 10-50% of adults over 60, contributing substantially to disability, falls, and mortality [89]. PGC-1 α gene therapy addresses multiple pathogenic mechanisms simultaneously: enhancing mitochondrial ATP

production to meet energy demands, preserving neuromuscular junction integrity to prevent denervation, promoting protein synthesis while suppressing degradation pathways, and

maintaining satellite cell regenerative capacity [90].

Clinical development strategies focus initially on focal delivery to small muscle groups in frail elderly patients, establishing safety before systemic administration [91].

Primary endpoints include muscle mass by MRI, strength by standardized dynamometry, and mitochondrial function by ³¹P-magnetic resonance spectroscopy [92]. Secondary outcomes encompass functional measures (6-minute walk test, timed up-and-go) and quality of life assessments [93].

Metabolic Disorders

Type 2 diabetes and metabolic syndrome represent major applications given PGC-1 α 's central role in glucose and lipid metabolism. Muscle-directed therapy could enhance insulin sensitivity through multiple mechanisms: increased GLUT4 expression and glucose uptake, enhanced mitochondrial oxidative capacity preventing lipotoxicity, and favorable modulation of myokine secretion [94].

However, hepatic delivery requires careful consideration given PGC-1 α 's gluconeogenic effects, which could potentially exacerbate hyperglycemia without appropriate regulation [95].

Safety Concern	Mechanism	Risk Level	Monitoring	Mitigation Strategy
Energy imbalance	↑ metabolic rate	Low-moderate	Weight, body composition	Dose optimization
Hypoglycemia	↑ glucose oxidation	Low	Blood glucose	Regulated expression
Cancer risk	Metabolic flexibility	Context-dependent	Tumor markers	Tissue targeting
Immune response	AAV antibodies	Moderate	NAbs, T-cells	Immunosuppression
Liver gluconeogenesis	↑ glucose production	Low	Liver enzymes, glucose	Muscle-specific delivery

Table 6: Safety Considerations and Monitoring.

Neurodegenerative Diseases

Parkinson's disease represents the most advanced neurodegenerative target based on preclinical evidence and established delivery methods. Stereotactic injection of AAV-PGC-1 α into the substantia nigra could provide neuroprotection while minimizing systemic effects [96].

Primary endpoints include motor function assessments (UPDRS scores), dopamine transporter imaging, and safety monitoring [97]. However, conflicting preclinical data necessitates careful patient selection and monitoring.

Alzheimer's disease poses greater challenges due to widespread pathology requiring broad brain delivery. Strategies include intrathecal administration for CSF distribution or engineered AAV variants with enhanced CNS tropism [98].

Biomarker endpoints (CSF amyloid- β , tau, neurofilament light chain) could demonstrate target engagement before cognitive benefits emerge [99].

Cardiovascular Disease

Heart failure patients could benefit from enhanced cardiac mitochondrial function through PGC-1 α gene therapy. Preclinical studies demonstrate improved cardiac energetics, reduced pathological hypertrophy, and enhanced exercise tolerance [100].

AAV9 shows excellent cardiac tropism following systemic delivery, with the cardiac troponin T promoter providing specificity [101]. Clinical endpoints include ejection

fraction, exercise capacity, and NT-proBNP levels [102].

Safety Considerations

Metabolic Homeostasis

The primary safety concern involves potential disruption of metabolic homeostasis from uncontrolled PGC-1 α expression. Excessive levels could theoretically cause hypoglycemia through enhanced glucose oxidation, though this has not been observed at therapeutic doses in most preclinical studies [103].

However, some studies report paradoxical effects including insulin resistance with very high expression levels [86]. Muscle wasting from hypermetabolism represents another theoretical risk, though transgenic mice maintain normal body weight despite increased energy expenditure [104].

Cancer Risk Assessment

While PGC-1 α generally exhibits tumor-suppressive properties through promotion of oxidative metabolism, context-dependent effects require consideration.

Some studies suggest PGC-1 α may support metastatic potential in specific cancer types including melanoma and certain breast cancer subsets by enhancing metabolic flexibility [105].

However, long-term studies in PGC-1 α transgenic mice show no increased cancer incidence over 2-year observation periods [106]. Risk mitigation strategies include tissue-specific promoters avoiding expression in tissues prone to malignancy [107].

Immunogenicity

AAV vectors can trigger immune responses limiting efficacy and potentially causing adverse effects. Pre-existing neutralizing antibodies, present in 40-70% of adults depending on serotype, may prevent transduction [108].

Cellular immune responses against capsid proteins can eliminate transduced cells, while transgene-specific immunity could develop against PGC-1 α if recognized as foreign [109]. Strategies include pre-screening for neutralizing antibodies, immunosuppressive regimens, and capsid engineering to reduce immunogenicity [110].




Figure 7: Clinical development pathway and biomarker strategy for PGC-1 α gene therapy.

Comprehensive timeline showing: Baseline assessments including PPARGC1A genotyping (Gly482Ser polymorphism), muscle biopsy for endogenous PGC-1 α expression and mitochondrial content, functional testing (6-minute walk test, grip strength, VO₂max), and serological markers (lactate, pyruvate, creatine kinase). Post-treatment monitoring schedule at 2, 4, 8, 12, and 24 weeks including: molecular markers (PGC-1 α mRNA/protein by muscle biopsy, mitochondrial DNA copy number, respiratory chain enzyme activities); biochemical parameters (serum lactate/pyruvate ratio, acylcarnitine profiles, inflammatory markers); functional outcomes (standardized strength testing, endurance measures, quality of life scores); and safety monitoring (liver enzymes, glucose homeostasis, cardiac function by echocardiography).

Future Directions

Combination Therapies

Synergistic approaches combining PGC-1α gene therapy with complementary interventions could maximize therapeutic benefits. Exercise training

naturally activates endogenous PGC-1α signaling, potentially amplifying effects of gene therapy [111]. Pharmacological agents including metformin (AMPK activation), NAD⁺ precursors (SIRT1 activation), and PPAR agonists could enhance PGC-1α activity through post-translational modifications [112].




Figure 8: Synergistic therapeutic strategies combining PGC-1α gene therapy with complementary interventions.

Schematic showing PGC-1α gene therapy as central intervention with four complementary approaches: **1:** Exercise prescription - aerobic and resistance training protocols to amplify PGC-1α signaling through AMPK/p38 MAPK activation; **2:** Pharmacological agents - metformin (AMPK activation), NAD⁺ precursors (nicotinamide riboside for SIRT1 activation), resveratrol (SIRT1 activation), and PPARδ agonists (GW501516); **3:** Nutritional interventions - caloric restriction mimetics, ketogenic diet to enhance mitochondrial adaptation; **4:** Combination gene therapy - co-delivery vectors expressing klotho (anti-aging), SIRT1 (deacetylation), or TERT (telomerase) to address multiple aging pathways. Central diagram shows convergence on mitochondrial biogenesis, oxidative capacity, and healthspan extension.

Next-Generation Vectors

Advanced vector engineering promises improved safety and efficacy. Synthetic AAV capsids selected through directed evolution show enhanced tissue specificity and reduced immunogenicity [113].

Self-complementary AAV vectors enable faster onset of expression, though with reduced packaging capacity [114]. Non-viral delivery systems including lipid nanoparticles offer alternative approaches avoiding anti-AAV immunity [115].

Precision Medicine Approaches

Genetic stratification could identify optimal candidates for PGC-1 α gene therapy. Individuals with loss-of-function PPARGC1A variants or epigenetic silencing may show enhanced responses [116].

Biomarker-guided dosing using circulating cell-free mitochondrial DNA or serum PGC-1 α levels could enable personalized treatment optimization [117].

Conclusion

PGC-1 α gene therapy represents a promising approach for addressing age-related metabolic dysfunction through enhancement of fundamental cellular energetics.

The convergence of detailed molecular understanding, compelling preclinical evidence, and advancing gene delivery technologies positions this intervention for clinical translation.

By targeting the core mechanism of mitochondrial dysfunction underlying multiple age-related diseases, PGC-1 α gene therapy offers

potential for simultaneous improvement in physical function, metabolic health, and cognitive performance.

However, important considerations temper this optimism. Conflicting preclinical data, particularly regarding neurodegenerative applications, necessitates careful patient selection and monitoring.

The context-dependent effects of PGC-1 α overexpression, including potential metabolic disruption at high doses, require precise expression control strategies. Additionally, the field awaits results from clinical trials to validate preclinical findings in human populations.

Careful attention to safety considerations, optimal delivery strategies, and patient selection will be critical for successful clinical development. As the global population ages, interventions enhancing healthspan through improved cellular bioenergetics become increasingly vital, with PGC-1 α gene therapy representing a scientifically grounded paradigm for achieving this goal, pending further validation through rigorous clinical investigation.

Conflict of Interest Statement

Dr. Patrick E. Sewell is the founder, CEO, and Chief Scientist of TripleHelix (triplehelixscience.com), a company offering gene therapies mentioned in this review. The author declares that this relationship has not influenced the objectivity of the scientific content presented.

Data Availability Statement

All data discussed in this review are available from the cited sources. No new data were generated for this review.

References

1. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. *Cell*. 1998;92(6):829-39.
2. Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V, et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. *Cell*. 1999;98(1):115-24.
3. Lin J, Handschin C, Spiegelman BM. Metabolic control through the PGC-1 family of transcription coactivators. *Cell Metab*. 2005;1(6):361-70.
4. Scarpulla RC. Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. *Biochim Biophys Acta*. 2011;1813(7):1269-78.
5. Egan B and Zierath JR. Exercise metabolism and the molecular regulation of skeletal muscle adaptation. *Cell Metab*. 2013;17(2):162-84.
6. Pilegaard H, Saltin B, Neufer PD. Exercise induces transient transcriptional activation of the PGC-1alpha gene in human skeletal muscle. *J Physiol*. 2003;546(Pt 3):851-8.
7. Handschin C and Spiegelman BM. The role of exercise and PGC1alpha in inflammation and chronic disease. *Nature*. 2008;454(7203):463-9.
8. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. *Cell*. 2013;153(6):1194-217.
9. Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, Goodspeed K, Gray SJ, Kay CN, et al. Current Clinical Applications of In Vivo Gene Therapy with AAVs. *Mol Ther*. 2021;29(2):464-88.
10. Esterbauer H, Oberkofler H, Krempler F, Patsch W. Human peroxisome proliferator activated receptor gamma coactivator 1 (PPARGC1) gene: cDNA sequence, genomic organization, chromosomal localization, and tissue expression. *Genomics*. 1999;62(1):98-102.
11. Monsalve M, Wu Z, Adelmant G, Puigserver P, Fan M, Spiegelman BM. Direct coupling of transcription and mRNA processing through the thermogenic coactivator PGC-1. *Mol Cell*. 2000;6(2):307-16.
12. Martínez-Redondo V, Pettersson AT, Ruas JL. The hitchhiker's guide to PGC-1α isoform structure and biological functions. *Diabetologia*. 2015;58(9):1969-77.
13. Jäger S, Handschin C, St-Pierre J, Spiegelman BM. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. *Proc Natl Acad Sci U S A*. 2007;104(29):12017-22.
14. Puigserver P, Rhee J, Lin J, Wu Z, Yoon JC, Zhang CY, et al. Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARGgamma coactivator-1. *Mol Cell*. 2001;8(5):971-82.
15. Lerin C, Rodgers JT, Kalume DE, Kim SH, Pandey A, Puigserver P. GCN5 acetyltransferase complex controls glucose metabolism through transcriptional repression of PGC-1alpha. *Cell Metab*. 2006;3(6):429-38.
16. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. *Nature*. 2005;434(7029):113-8.
17. Teyssier C, Ma H, Emter R, Kralli A, Stallcup MR. Activation of nuclear receptor coactivator PGC-1alpha by arginine methylation. *Genes Dev*. 2005;19(12):1466-73.
18. Olson BL, Hock MB, Ekholm-Reed S, Wohlschlegel JA, Dev KK, Kralli A, et al. SCFCdc4 acts antagonistically to the PGC-1alpha transcriptional coactivator by targeting it for ubiquitin-mediated proteolysis. *Genes Dev*. 2008;22(2):252-64.
19. Ling C, Poulsen P, Carlsson E, Ridderstråle M, Almgren P, Wojtaszewski J, et al. Multiple environmental and genetic factors influence skeletal muscle PGC-1alpha and PGC-1beta gene expression in twins. *J Clin Invest*. 2004;114(10):1518-26.
20. Short KR, Bigelow ML, Kahl J, Singh R, Coenen-Schimke J, Raghavakaimal S, et al. Decline in skeletal muscle mitochondrial function with aging in humans. *Proc Natl Acad Sci U S A*. 2005;102(15):5618-23.
21. Qin W, Haroutunian V, Katsel P, Cardozo CP, Ho L, Buxbaum JD, et al. PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia. *Arch Neurol*. 2009;66(3):352-61.

22. Barrès R, Osler ME, Yan J, Rune A, Fritz T, Caidahl K, et al. Non-CpG methylation of the PGC-1 α promoter through DNMT3B controls mitochondrial density. *Cell Metab.* 2009;10(3):189-98.
23. Alvarez-Guardia D, Palomer X, Coll T, Davidson MM, Chan TO, Feldman AM, et al. The p65 subunit of NF-kappaB binds to PGC-1 α , linking inflammation and metabolic disturbances in cardiac cells. *Cardiovasc Res.* 2010;87(3):449-58.
24. St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jäger S, et al. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. *Cell.* 2006;127(2):397-408.
25. Virbasius JV and Scarpulla RC. Activation of the human mitochondrial transcription factor A gene by nuclear respiratory factors: a potential regulatory link between nuclear and mitochondrial gene expression in organelle biogenesis. *Proc Natl Acad Sci U S A.* 1994;91(4):1309-13.
26. Scarpulla RC. Nuclear control of respiratory chain expression by nuclear respiratory factors and PGC-1-related coactivator. *Ann N Y Acad Sci.* 2008;1147:321-34.
27. Campbell CT, Kolesar JE, Kaufman BA. Mitochondrial transcription factor A regulates mitochondrial transcription initiation, DNA packaging, and genome copy number. *Biochim Biophys Acta.* 2012;1819(9-10):921-9.
28. Soriano FX, Liesa M, Bach D, Chan DC, Palacín M, Zorzano A. Evidence for a mitochondrial regulatory pathway defined by peroxisome proliferator-activated receptor-gamma coactivator-1 α , estrogen-related receptor- α , and mitofusin 2. *Diabetes.* 2006;55(6):1783-91.
29. Liesa M and Shirihai OS. Mitochondrial dynamics in the regulation of nutrient utilization and energy expenditure. *Cell Metab.* 2013;17(4):491-506.
30. Vainshtein A, Desjardins EM, Armani A, Sandri M, Hood DA. PGC-1 α modulates denervation-induced mitophagy in skeletal muscle. *Skelet Muscle.* 2015;5:9.
31. Vega RB, Huss JM, Kelly DP. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor α in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. *Mol Cell Biol.* 2000;20(5):1868-76.
32. Summermatter S, Baum O, Santos G, Hoppeler H, Handschin C. Peroxisome proliferator-activated receptor {gamma} coactivator 1{alpha} (PGC-1{alpha}) promotes skeletal muscle lipid refueling in vivo by activating de novo lipogenesis and the pentose phosphate pathway. *J Biol Chem.* 2010;285(43):32793-800.
33. Wende AR, Schaeffer PJ, Parker GJ, Zechner C, Han DH, Chen MM, et al. A role for the transcriptional coactivator PGC-1 α in muscle refueling. *J Biol Chem.* 2007;282(50):36642-51.
34. Michael LF, Wu Z, Cheatham RB, Puigserver P, Adelmant G, Lehman JJ, et al. Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1. *Proc Natl Acad Sci U S A.* 2001;98(7):3820-5.
35. Yoon JC, Puigserver P, Chen G, Donovan J, Wu Z, Rhee J, et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. *Nature.* 2001;413(6852):131-8.
36. Rhee J, Inoue Y, Yoon JC, Puigserver P, Fan M, Gonzalez FJ, et al. Regulation of hepatic fasting response by PPARGgamma coactivator-1 α (PGC-1): requirement for hepatocyte nuclear factor 4 α in gluconeogenesis. *Proc Natl Acad Sci U S A.* 2003;100(7):4012-17.
37. Schiaffino S and Reggiani C. Fiber types in mammalian skeletal muscles. *Physiol Rev.* 2011;91(4):1447-531.
38. Handschin C, Chin S, Li P, Liu F, Maratos-Flier E, LeBrasseur NK, et al. Skeletal muscle fiber-type switching, exercise intolerance, and myopathy in PGC-1 α muscle-specific knock-out animals. *J Biol Chem.* 2007;282(41):30014-21.
39. Summermatter S, Thurnheer R, Santos G, Mosca B, Baum O, Treves S, et al. Remodeling of calcium handling in skeletal muscle through PGC-1 α : impact on force, fatigability, and fiber type. *Am J Physiol Cell Physiol.* 2012;302(1):C88-99.
40. Arany Z, Foo SY, Ma Y, Ruas JL, Bommi-Reddy A, Girnun G, et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1 α . *Nature.* 2008;451(7181):1008-12.

41. Rowe GC, El-Khoury R, Patten IS, Rustin P, Arany Z. PGC-1 α is dispensable for exercise-induced mitochondrial biogenesis in skeletal muscle. *PLoS One*. 2012;7(7):e41817.
42. Valle I, Alvarez-Barrientos A, Arza E, Lamas S, Monsalve M. PGC-1 α regulates the mitochondrial antioxidant defense system in vascular endothelial cells. *Cardiovasc Res*. 2005;66(3):562-73.
43. Austin S and St-Pierre J. PGC1 α and mitochondrial metabolism--emerging concepts and relevance in ageing and neurodegenerative disorders. *J Cell Sci*. 2012;125(Pt 21):4963-71.
44. Wrann CD, White JP, Salogiannis J, Laznik-Bogoslavski D, Wu J, Ma D, et al. Exercise induces hippocampal BDNF through a PGC-1 α /FND5 pathway. *Cell Metab*. 2013;18(5):649-59.
45. Cheng A, Wan R, Yang JL, Kamimura N, Son TG, Ouyang X, et al. Involvement of PGC-1 α in the formation and maintenance of neuronal dendritic spines. *Nat Commun*. 2012;3:1250.
46. Sweeney G and Song J. The association between PGC-1 α and Alzheimer's disease. *Anat Cell Biol*. 2016;49(1):1-6.
47. Lin J, Wu H, Tarr PT, Zhang CY, Wu Z, Boss O, et al. Transcriptional co-activator PGC-1 α drives the formation of slow-twitch muscle fibres. *Nature*. 2002;418(6899):797-801.
48. Calvo JA, Daniels TG, Wang X, Paul A, Lin J, Spiegelman BM, et al. Muscle-specific expression of PPAR γ coactivator-1 α improves exercise performance and increases peak oxygen uptake. *J Appl Physiol*. 2008;104(5):1304-12.
49. Summermatter S, Shui G, Maag D, Santos G, Wenk MR, Handschin C. PGC-1 α improves glucose homeostasis in skeletal muscle in an activity-dependent manner. *Diabetes*. 2013;62(1):85-95.
50. Benton CR, Wright DC, Bonen A. PGC-1 α -mediated regulation of gene expression and metabolism: implications for nutrition and exercise prescriptions. *Appl Physiol Nutr Metab*. 2008;33(5):843-62.
51. Kleiner S, Mepani RJ, Laznik D, Ye L, Jurczak MJ, Jornayvaz FR, et al. Development of insulin resistance in mice lacking PGC-1 α in adipose tissues. *Proc Natl Acad Sci U S A*. 2012;109(24):9635-40.
52. Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, et al. A PGC1- α -dependent myokine that drives brown-fat-like development of white fat and thermogenesis. *Nature*. 2012;481(7382):463-8.
53. Mudo G, Mäkelä J, Liberto VD, Tselykh TV, Olivieri M, Piepponen P, et al. Transgenic expression and activation of PGC-1 α protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease. *Cell Mol Life Sci*. 2012;69(7):1153-65.
54. Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, et al. PGC-1 α , a potential therapeutic target for early intervention in Parkinson's disease. *Sci Transl Med*. 2010;2(52):52ra73.
55. Corona JC and Duchon MR. PPAR γ and PGC-1 α as therapeutic targets in Parkinson's. *Neurochem Res*. 2015;40(2):308-16.
56. Katsouri L, Parr C, Bogdanovic N, Willem M, Sastre M. PPAR γ co-activator-1 α (PGC-1 α) reduces amyloid- β generation through a PPAR γ -dependent mechanism. *J Alzheimers Dis*. 2011;25(1):151-62.
57. Katsouri L, Lim YM, Blondrath K, Eleftheriadou I, Lombardero L, Birch AM, et al. PPAR γ -coactivator-1 α gene transfer reduces neuronal loss and amyloid- β generation by reducing β -secretase in an Alzheimer's disease model. *Proc Natl Acad Sci U S A*. 2016;113(43):12292-7.
58. Wenz T, Rossi SG, Rotundo RL, Spiegelman BM, Moraes CT. Increased muscle PGC-1 α expression protects from sarcopenia and metabolic disease during aging. *Proc Natl Acad Sci U S A*. 2009;106(48):20405-10.
59. Sandri M, Lin J, Handschin C, Yang W, Arany ZP, Lecker SH, et al. PGC-1 α protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. *Proc Natl Acad Sci U S A*. 2006;103(44):16260-5.
60. Arnold AS, Gill J, Christe M, Ruiz R, McGuirk S, St-Pierre J, et al. Morphological and functional remodelling of the neuromuscular junction by skeletal muscle PGC-1 α . *Nat Commun*. 2014;5:3569.
61. Dufour CR, Wilson BJ, Huss JM, Kelly DP, Alaynick WA, Downes M, et al. Genome-wide orchestration of cardiac functions by the orphan nuclear receptors ERR α and γ . *Cell Metab*. 2007;5(5):345-56.
62. Ciron C, Lengacher S, Dusonchet J, Aebischer P, Schneider BL. Sustained expression of PGC-1 α in the rat nigrostriatal system selectively impairs dopaminergic function. *Hum Mol Genet*. 2012;21(8):1861-76.

63. Huss JM, Torra IP, Staels B, Giguère V, Kelly DP. Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. *Mol Cell Biol.* 2004;24(20):9079-91.
64. Wang Z, Zhu T, Qiao C, Zhou L, Wang B, Zhang J, et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. *Nat Biotechnol.* 2005;23(3):321-8.
65. Ek J, Andersen G, Urhammer SA, Gaede PH, Drivsholm T, Borch-Johnsen K, et al. Mutation analysis of peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to Type II diabetes mellitus. *Diabetologia.* 2001;44(12):2220-6.
66. Barroso I, Luan J, Sandhu MS, Franks PW, Crowley V, Schafer AJ et al. Meta-analysis of the Gly482Ser variant in PPARGC1A in type 2 diabetes and related phenotypes. *Diabetologia.* 2006;49(3):501-5.
67. Lucia A, Gómez-Gallego F, Barroso I, Rabadán M, Bandrés F, San Juan AF, et al. PPARGC1A genotype (Gly482Ser) predicts exceptional endurance capacity in European men. *J Appl Physiol.* 2005;99(1):344-8.
68. Franks PW, Barroso I, LUAN JA, Ekelund U, Crowley VE, Brage S, et al. PGC-1alpha genotype modifies the association of volitional energy expenditure with [OV0312]O2max. *Med Sci Sports Exerc.* 2003;35(12):1998-2004.
69. Conley KE, Jubrias SA, Esselman PC. Oxidative capacity and ageing in human muscle. *J Physiol.* 2000;526 Pt 1:203-10.
70. Lanza IR, Short DK, Short KR, Raghavakaimal S, Basu R, Joyner MJ, et al. Endurance exercise as a countermeasure for aging. *Diabetes.* 2008;57(11):2933-42.
71. Perry CG, Lally J, Holloway GP, Heigenhauser GJ, Bonen A, Spriet LL. Repeated transient mRNA bursts precede increases in transcriptional and mitochondrial proteins during training in human skeletal muscle. *J Physiol.* 2010;588(Pt 23):4795-10.
72. Norrbom J, Sundberg CJ, Ameln H, Kraus WE, Jansson E, Gustafsson T. PGC-1alpha mRNA expression is influenced by metabolic perturbation in exercising human skeletal muscle. *J Appl Physiol.* 2004;96(1):189-94.
73. Mensink M, Hesselink MK, Russell AP, Schaart G, Sels JP, Schrauwen P. Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPAR beta/delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus. *Int J Obes.* 2007;31(8):1302-10.
74. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. *Nat Genet.* 2003;34(3):267-73.
75. Wu Z, Yang H, Colosi P. Effect of genome size on AAV vector packaging. *Mol Ther.* 2010;18(1):80-6.
76. Wright JF. Manufacturing and characterizing AAV-based vectors for use in clinical studies. *Gene Ther.* 2008;15(11):840-8.
77. Hakim CH, Wasala NB, Nelson CE, Wasala LP, Yue Y, Louderman JA, et al. AAV CRISPR editing rescues cardiac and muscle function for 18 months in dystrophic mice. *JCI Insight.* 2018;3(23):e124297.
78. Prasad KM, Xu Y, Yang Z, Acton ST, French BA. Robust cardiomyocyte-specific gene expression following systemic injection of AAV: in vivo gene delivery follows a Poisson distribution. *Gene Ther.* 2011;18(1):43-52.
79. Kügler S, Kilic E, Bähr M. Human synapsin 1 gene promoter confers highly neuron-specific long-term transgene expression from an adenoviral vector in the adult rat brain depending on the transduced area. *Gene Ther.* 2003;10(4):337-47.
80. Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. *Mol Ther.* 2008;16(6):1073-80.
81. Inagaki K, Fuess S, Storm TA, Gibson GA, Mctiernan CF, Kay MA, et al. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. *Mol Ther.* 2006;14(1):45-53.
82. Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. *Nat Biotechnol.* 2009;27(1):59-65.

83. Deverman BE, Pravdo PL, Simpson BP, Kumar SR, Chan KY, Banerjee A, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. *Nat Biotechnol.* 2016;34(2):204-9.
84. Bartus RT, Baumann TL, Siffert J, Herzog CD, Alterman R, Boulis N, et al. Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. *Neurology.* 2013;80(18):1698-701.
85. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. *Nat Med.* 2006;12(3):342-7.
86. Choi CS, Befroy DE, Codella R, Kim S, Reznick RM, Hwang YJ, et al. Paradoxical effects of increased expression of PGC-1alpha on muscle mitochondrial function and insulin-stimulated muscle glucose metabolism. *Proc Natl Acad Sci U S A.* 2008;105(50):19926-31.
87. Das AT, Tenenbaum L, Berkhout B. Tet-On Systems For Doxycycline-inducible Gene Expression. *Curr Gene Ther.* 2016;16(3):156-67.
88. Akimoto T, Sorg BS, Yan Z. Real-time imaging of peroxisome proliferator-activated receptor-gamma coactivator-1alpha promoter activity in skeletal muscles of living mice. *Am J Physiol Cell Physiol.* 2004;287(3):C790-6.
89. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing.* 2019;48(1):16-31.
90. Morley JE, Anker SD, von Haehling S. Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update 2014. *J Cachexia Sarcopenia Muscle.* 2014;5(4):253-9.
91. Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. *J Am Med Dir Assoc.* 2020;21(3):300-7.e2.
92. Reginster JY, Cooper C, Rizzoli R, Kanis JA, Appelboom G, Bautmans I, et al. Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia. *Aging Clin Exp Res.* 2016;28(1):47-58.
93. Beaudart C, Biver E, Reginster JY, Rizzoli R, Rolland Y, Bautmans I, et al. Validation of the SarQoL®, a specific health-related quality of life questionnaire for Sarcopenia. *J Cachexia Sarcopenia Muscle.* 2017;8(2):238-44.
94. Lira VA, Benton CR, Yan Z, Bonen A. PGC-1alpha regulation by exercise training and its influences on muscle function and insulin sensitivity. *Am J Physiol Endocrinol Metab.* 2010;299(2):E145-61.
95. Koo SH, Satoh H, Herzig S, Lee CH, Hedrick S, Kulkarni R, et al. PGC-1 promotes insulin resistance in liver through PPAR-alpha-dependent induction of TRB-3. *Nat Med.* 2004;10(5):530-4.
96. LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, et al. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. *Lancet Neurol.* 2011;10(4):309-19.
97. Christine CW, Starr PA, Larson PS, Eberling JL, Jagust WJ, Hawkins RA, et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. *Neurology.* 2009;73(20):1662-9.
98. Rafii MS, Tuszynski MH, Thomas RG, Barba D, Brewer JB, Rissman RA, et al. Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial. *JAMA Neurol.* 2018;75(7):834-41.
99. Hampel H, O'Bryant SE, Molinuevo JL, Zetterberg H, Masters CL, Lista S, et al. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. *Nat Rev Neurol.* 2018;14(11):639-52.
100. Lehman JJ and Kelly DP. Gene regulatory mechanisms governing energy metabolism during cardiac hypertrophic growth. *Heart Fail Rev.* 2002;7(2):175-85.
101. Bish LT, Morine K, Sleeper MM, Sanmiguel J, Wu D, Gao G, et al. Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. *Hum Gene Ther.* 2008;19(12):1359-68.
102. Greenberg B, Butler J, Felker GM, Ponikowski P, Voors AA, Desai AS, et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. *Lancet.* 2016;387(10024):1178-86.

103. Miura S, Kai Y, Kamei Y, Ezaki O. Isoform-specific increases in murine skeletal muscle peroxisome proliferator-activated receptor-gamma coactivator-1alpha (PGC-1alpha) mRNA in response to beta2-adrenergic receptor activation and exercise. *Endocrinology*. 2008;149(9):4527-33.
104. Garcia-Roves PM, Osler ME, Holmström MH, Zierath JR. Gain-of-function R225Q mutation in AMP-activated protein kinase gamma3 subunit increases mitochondrial biogenesis in glycolytic skeletal muscle. *J Biol Chem*. 2008;283(51):35724-34.
105. Luo C, Lim JH, Lee Y, Granter SR, Thomas A, Vazquez F, et al. A PGC1 α -mediated transcriptional axis suppresses melanoma metastasis. *Nature*. 2016;537(7620):422-6.
106. Dillon LM, Rebelo AP, Moraes CT. The role of PGC-1 coactivators in aging skeletal muscle and heart. *IUBMB Life*. 2012;64(3):231-41.
107. Tan Z, Luo X, Xiao L, Tang M, Bode AM, Dong Z, et al. The Role of PGC1 α in Cancer Metabolism and its Therapeutic Implications. *Mol Cancer Ther*. 2016;15(5):774-82.
108. Mingozzi F and High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. *Blood*. 2013;122(1):23-36.
109. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. *N Engl J Med*. 2011;365(25):2357-65.
110. Li C and Samulski RJ. Engineering adeno-associated virus vectors for gene therapy. *Nat Rev Genet*. 2020;21(4):255-72.
111. Booth FW, Roberts CK, Laye MJ. Lack of exercise is a major cause of chronic diseases. *Compr Physiol*. 2012;2(2):1143-211.
112. Cantó C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, et al. AMPK regulates energy expenditure by modulating NAD⁺ metabolism and SIRT1 activity. *Nature*. 2009;458(7241):1056-60.
113. Ogden PJ, Kelsic ED, Sinai S, Church GM. Comprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design. *Science*. 2019;366(6469):1139-43.
114. McCarty DM. Self-complementary AAV vectors; advances and applications. *Mol Ther*. 2008;16(10):1648-56.
115. Cullis PR and Hope MJ. Lipid Nanoparticle Systems for Enabling Gene Therapies. *Mol Ther*. 2017;25(7):1467-75.
116. Gusella GL, Fedorova E, Hanss B, Marras D, Klotman ME, Klotman PE. Lentiviral gene transduction of kidney. *Hum Gene Ther*. 2002;13(3):407-14.
117. An HJ, Shin H, Jo SG, et al. The survival effect of mitochondrial biogenesis regulators on endothelial cells under oxidative stress and its clinical application for chronic limb-threatening ischemia. *J Vasc Surg*. 2022;75(5):1708-20.e8.